Enanta Pharma (ENTA) Misses Q4 EPS by 2c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.27), $0.02 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $20.32 million versus the consensus estimate of $22.87 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Super Micro Computer rises on AI server market optimism
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)